Compare ClearPoint Neuro Inc (CLPT) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

TCPC trades at $3.15, down 3.37% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025 despite a 112% net income margin, driven by negative revenue. Analyst consensus shows mixed sentiment with 31% buy ratings, while recent news includes a Zacks upgrade and upcoming Q2 earnings on August 6, 2026.

The outlook remains challenging with persistent negative revenue and profitability issues. Investment opportunities include the low P/B ratio of 0.47 and dividend yield, but risks include ongoing losses, shareholder litigation, and bearish technical indicators. The stock faces significant fundamental headwinds despite some analyst optimism.